

## **PanTera produces and supplies first Actinium-225 extracted from Thorium-229 in Belgium.**

**Mol, Belgium – 12 June 2025** – PanTera is pleased to announce a significant milestone in its mission to support the advancement of targeted alpha radiotherapy for cancer treatment. The company has successfully extracted and supplied Actinium-225 (Ac-225) from its Thorium-229 (Th-229) generator, installed at its production facility in Belgium. This achievement marks the first delivery of Ac-225 under PanTera's "Early Supply" program, powered by Th-229 material provided by TerraPower Isotopes. The program is set to deliver over 1.5 curies of Ac-225 annually, which could benefit thousands of patients worldwide.

“We are deeply grateful to all stakeholders who contributed to this accomplishment, particularly our collaborators at TerraPower Isotopes for their unwavering collaboration and support,” said **Sven Van den Berghe**, CEO of PanTera. “Without their supply of Th-229 and the suitable infrastructure we could access at SCK CEN, this achievement would not have been possible on such short notice. This milestone not only highlights the technical expertise of PanTera's team in producing high-purity Ac-225 but also solidifies our position at the forefront of Targeted Alpha Therapy (TAT) radioisotope supply.”

**Scott Claunch**, President of TerraPower Isotopes (TPI), commented, “We are thrilled with PanTera's successful delivery of Ac-225 produced from our Thorium-229 supply. This achievement represents a critical step forward in our collaboration with PanTera and brings much-needed additional Ac-225 to the global market, ultimately transforming the treatment options available to cancer patients around the world.”

This milestone sets the stage for PanTera's ambitious plans to expand its production capabilities. The company is preparing for its large-scale Actinium Production Centre (APC), which will deliver over 100 curies of Ac-225 annually using its innovative gamma irradiation process. Following a successful venture capital raise of nearly 100 million euros last September, PanTera has made remarkable progress in de-risking its technology and advancing its production capabilities. With several additional milestones anticipated in the coming months, PanTera is confident it will emerge as one of the most critical enablers of commercial-scale Ac-225-based targeted radiotherapy globally by the end of the decade.

## **A Game-Changer in Targeted Alpha Therapy**

Actinium-225 is a promising alpha-emitting radioisotope used in Targeted Alpha Therapy (TAT) for cancer treatment. Its ability to deliver high-energy radiation directly to cancer cells while minimizing damage to surrounding healthy tissue makes it a valuable component in developing effective cancer therapies. PanTera's facility aims to secure the large-scale production of Ac-225, improving accessibility to innovative cancer treatments worldwide.

### **About PanTera**

PanTera originated as a joint venture between IBA and SCK CEN, established to secure the large-scale production of actinium-225 (Ac-225), a promising alpha-emitting radioisotope for targeted cancer therapies. With a Series A funding of €95.6 million and all necessary building blocks available, PanTera is ideally positioned to develop cutting-edge production capabilities to enable the accessibility of innovative cancer treatments based on Ac-225.

PanTera's production strategy is built on two complementary approaches: an Early Supply production leveraging Thorium-229 decay, which will provide Ac-225 as early as 2025, and a Commercial Supply production utilizing the Ra-226 photonuclear reaction to enable large-scale commercial production by 2028. These initiatives ensure a sustainable and scalable supply chain to meet the growing global demand for Ac-225. <https://pantera-life.com/>

**For more information, please contact:**

**PanTera** – Sven Van den Berghe – [info@Pantera-life.com](mailto:info@Pantera-life.com)